KALA vs. AGLE, BTAI, ANVS, VHAQ, MNOV, CKPT, LTRN, AFMD, RLYB, and ELDN
Should you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Aeglea BioTherapeutics (AGLE), BioXcel Therapeutics (BTAI), Annovis Bio (ANVS), Viveon Health Acquisition (VHAQ), MediciNova (MNOV), Checkpoint Therapeutics (CKPT), Lantern Pharma (LTRN), Affimed (AFMD), Rallybio (RLYB), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical preparations" industry.
KALA BIO (NASDAQ:KALA) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
In the previous week, KALA BIO had 5 more articles in the media than Aeglea BioTherapeutics. MarketBeat recorded 5 mentions for KALA BIO and 0 mentions for Aeglea BioTherapeutics. KALA BIO's average media sentiment score of 0.48 beat Aeglea BioTherapeutics' score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.
KALA BIO has a net margin of 0.00% compared to Aeglea BioTherapeutics' net margin of -22,195.36%. Aeglea BioTherapeutics' return on equity of -132.05% beat KALA BIO's return on equity.
KALA BIO currently has a consensus price target of $16.50, indicating a potential upside of 145.54%. Aeglea BioTherapeutics has a consensus price target of $17.50, indicating a potential upside of ∞. Given Aeglea BioTherapeutics' higher probable upside, analysts plainly believe Aeglea BioTherapeutics is more favorable than KALA BIO.
24.6% of KALA BIO shares are owned by institutional investors. 13.4% of KALA BIO shares are owned by insiders. Comparatively, 6.6% of Aeglea BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
KALA BIO received 44 more outperform votes than Aeglea BioTherapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave KALA BIO an outperform vote while only 56.70% of users gave Aeglea BioTherapeutics an outperform vote.
KALA BIO has higher revenue and earnings than Aeglea BioTherapeutics. KALA BIO is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
KALA BIO has a beta of -1.75, indicating that its share price is 275% less volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500.
Summary
KALA BIO beats Aeglea BioTherapeutics on 13 of the 17 factors compared between the two stocks.
Get KALA BIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KALA BIO Competitors List
Related Companies and Tools
